Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Elizabeth J. Buss, Lisa A. Kachnic, David P. Horowitz
Summary: This review summarizes the expanding role of radiotherapy in the management of locally advanced, unresectable pancreatic cancer. Higher, ablative doses of radiation and advancements in technology have been shown to improve patient survival rates.
SEMINARS IN ONCOLOGY
(2021)
Article
Oncology
Maarten C. C. M. Hulshof, Elisabeth D. Geijsen, Tom Rozema, Vera Oppedijk, Jeroen Buijsen, Karen J. Neelis, Joost J. M. E. Nuyttens, Maurice J. C. van der Sangen, Paul M. Jeene, Jannie G. Reinders, Mark I. van Berge Henegouwen, Adriana Thano, Jeanin E. van Hooft, Hanneke W. M. van Laarhoven, Ate van der Gaast
Summary: In definitive chemoradiation for esophageal cancer, escalating radiation dose up to 61.6 Gy to the primary tumor did not significantly improve local tumor control compared to 50.4 Gy. The absence of a dose-effect was observed in both adenocarcinoma and squamous cell carcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
P. Travis Courtney, Anthony J. Paravati, Todd F. Atwood, Nandita Raja, Collin T. Zimmerman, Paul T. Fanta, Andrew M. Lowy, Daniel R. Simpson, Ronghui Xu, James D. Murphy
Summary: This study aimed to evaluate the tolerance and efficacy of high-dose SBRT in patients with pancreatic cancer, which showed favorable local control and survival outcomes but also high rates of severe late gastrointestinal toxicity.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Silvana Parisi, Gianluca Ferini, Alberto Cacciola, Sara Lillo, Consuelo Tamburella, Anna Santacaterina, Antonio Bottari, Anna Brogna, Giacomo Ferrantelli, Antonio Pontoriero, Fabio Minutoli, Stefano Pergolizzi
Summary: This study presents a non-surgical combo-therapy for locally advanced, unresectable pancreatic cancer, which includes induction chemotherapy, concomitant chemoradiotherapy, and stereotactic body radiotherapy boost. The therapy showed feasibility and good tolerance, achieving favorable local control and survival outcomes.
Review
Oncology
Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen, Per Pfeiffer
Summary: Pancreatic cancer is a leading cause of cancer-related death worldwide, and the management of locally advanced or metastatic disease is difficult due to limited treatment options. While systemic chemotherapy is commonly used, the role of radiotherapy in treatment remains unclear. This review explores the available data on radiotherapy, chemoradiation, and stereotactic body radiation therapy for locally advanced pancreatic cancer. The included studies showed conflicting results and high heterogeneity, highlighting the need for further research to improve outcomes and define the role of radiation therapy in pancreatic cancer.
Article
Oncology
Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. Denardo
Summary: The combination therapy of defactinib, pembrolizumab, and gemcitabine showed good tolerability and safety, promising preliminary efficacy, and biomarker activity in infiltrative T lymphocytes in PDAC patients.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Thorvardur R. Halfdanarson, Nathan R. Foster, George P. Kim, Michael G. Haddock, Shaker R. Dakhil, Robert J. Behrens, Steven R. Alberts
Summary: This study evaluated the efficacy of upfront chemoradiotherapy incorporating the EGFR inhibitor panitumumab for pancreatic cancer. The results showed a high rate of adverse events and the survival outcomes did not meet the expected goals.
Article
Oncology
Edouard Auclin, Lysiane Marthey, Raef Abdallah, Leo Mas, Eric Francois, Angelique Saint, Antonio Sa Cunha, Angelique Vienot, Thierry Lecomte, Vincent Hautefeuille, Christelle de la Fouchardiere, Matthieu Sarabi, Feryel Ksontini, Julien Forestier, Romain Coriat, Emmanuelle Fabiano, Florence Leroy, Nicolas Williet, Jean-Baptiste Bachet, David Tougeron, Julien Taieb
Summary: FOLFIRINOX shows promising efficacy with manageable toxicity in treating locally advanced or borderline resectable pancreatic adenocarcinoma. Surgical resection rates are low but significantly impact overall survival for patients.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Evelien J. M. de Jong, Quisette P. Janssen, Tessa F. A. Simons, Marc G. Besselink, Bert A. Bonsing, Stefan A. W. Bouwense, Sandra M. E. Geurts, Marjolein Y. Homs, Vincent E. de Meijer, Vivianne C. G. Tjan-Heijnen, Hanneke W. M. van Laarhoven, Liselot B. J. Valkenburg-van Iersel, Johanna W. Wilmink, Lydia G. van der Geest, Bas Groot Koerkamp, Judith de Vos-Geelen
Summary: In a nationwide cohort of patients with pancreatic ductal adenocarcinoma, adjuvant GEMCAP was associated with superior survival compared to GEM monotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Georgios Gemenetzis, Alex B. Blair, Minako Nagai, Vincent P. Groot, Ding Ding, Ammar A. Javed, Richard A. Burkhart, Elliot K. Fishman, Ralph H. Hruban, Matthew J. Weiss, John L. Cameron, Amol Narang, Daniel Laheru, Kelly Lafaro, Joseph M. Herman, Lei Zheng, William R. Burns, Christopher L. Wolfgang, Jin He
Summary: The study focused on locally advanced pancreatic cancer (LAPC) patients and found that the anatomical stratification system based on regional structures before treatment plays a significant role in determining the likelihood of surgical resection. Surgeons have a better judgment on the potential for surgical exploration based on the LAPC score during the exploratory operation, leading to improved outcomes for LAPC patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Durim Delishaj, Ilaria Costanza Fumagalli, Stefano Ursino, Agostino Cristaudo, Francesco Colangelo, Antonio Stefanelli, Alessandro Alghisi, Giuseppe De Nobili, Romerai D'Amico, Alessandra Cocchi, Antonio Ardizzoia, Carlo Pietro Soatti
Summary: The standard treatment for locally advanced rectal cancers is neoadjuvant chemoradiotherapy followed by surgery. Studies have shown benefits of radiotherapy dose escalation for tumor downstaging, but there is limited research on dose escalation using innovative techniques for LARC (T3-4 or N1-2). A review of literature suggests that neoadjuvant radiotherapy dose escalation using innovative techniques can achieve higher rates of pCR in LARC, but EQD2 doses greater than 58.9 Gy are associated with increased risk of surgical complications.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Biochemistry & Molecular Biology
Tadataka Takagi, Rina Fujiwara-Tani, Shiori Mori, Shingo Kishi, Yukiko Nishiguchi, Takamitsu Sasaki, Ruiko Ogata, Ayaka Ikemoto, Rika Sasaki, Hitoshi Ohmori, Yi Luo, Ujjal Kumar Bhawal, Masayuki Sho, Hiroki Kuniyasu
Summary: Gemcitabine resistance in pancreatic ductal adenocarcinoma cells is associated with decreased energy production, decreased mitochondrial reactive oxygen species levels, and increased stemness caused by mitochondrial damage. Hypoxia may promote this process. Treatment with lauric acid restores gemcitabine sensitivity by activating oxidative phosphorylation. Further clinical validation of lauric acid in gemcitabine resistance is needed in the future.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jung Hyun Jo, Dawoon E. Jung, Hee Seung Lee, Soo Been Park, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Sangsook Cho, Si Young Song
Summary: This phase I/II study evaluated the safety and efficacy of a new HDAC inhibitor called ivaltinostat in combination with gemcitabine and erlotinib for advanced PDAC. The study found that this combination therapy showed potential as a treatment option for PDAC.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Adriel Barrios-Anderson, Reshmitha Radhakrishnan, Esther Yu, Alexei Shimanovsky
Summary: This case report and literature review of RR myositis cases emphasizes the clinical course and presentation of RR myositis. It highlights the importance of considering RR in the differential diagnosis when patients undergoing chemotherapy and radiation therapy present with inflammatory changes in previously irradiated areas.
Article
Radiology, Nuclear Medicine & Medical Imaging
Elin Pauwels, Frederik Cleeren, Terence Tshibangu, Michel Koole, Kim Serdons, Lennert Boeckxstaens, Jeroen Dekervel, Timon Vandamme, Willem Lybaert, Bliede Van den Broeck, Annouschka Laenen, Paul M. Clement, Karen Geboes, Eric Van Cutsem, Sigrid Stroobants, Chris Verslype, Guy Bormans, Christophe M. Deroose
Summary: A recent multicenter trial demonstrated that 18F-AlF-OC, as a radiotracer, is noninferior to 68Ga-DOTA-SSA in somatostatin receptor imaging for neuroendocrine tumor patients. This study provides scientific evidence for the clinical application of 18F-AlF-OC.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Oncology
Lien van Walle, Geert Silversmit, Lieven Depypere, Philippe Nafteux, Hans Van Veer, Elke Van Daele, Yannick Deswysen, Jerome Xicluna, Annelies Debucquoy, Liesbet Van Eycken, Karin Haustermans
Summary: This population-based study supports the association between hospital volume and outcomes of esophageal cancer surgery. The findings suggest the need for centralization of esophageal resections in Belgium, in line with national health policy measures.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Simon K. B. Spohn, Cederic Draulans, Amar U. Kishan, Daniel Spratt, Ashley Ross, Tobias Maurer, Derya Tilki, Alejandro Berlin, Pierre Blanchard, Sean Collins, Peter Bronsert, Ronald Chen, Alan Dal Pra, Gert de Meerleer, Thomas Eade, Karin Haustermans, Tobias Holscher, Stefan Hocht, Pirus Ghadjar, Elai Davicioni, Matthias Heck, Linda G. W. Kerkmeijer, Simon Kirste, Nikolaos Tselis, Phuoc T. Tran, Michael Pinkawa, Pascal Pommier, Constantinos Deltas, Nina-Sophie Schmidt-Hegemann, Thomas Wiegel, Thomas Zilli, Alison C. Tree, Xuefeng Qiu, Vedang Murthy, Jonathan I. Epstein, Christian Graztke, Xin Gao, Anca L. Grosu, Sophia C. Kamran, Constantinos Zamboglou
Summary: Current risk-stratification systems for prostate cancer do not adequately reflect the disease heterogeneity. Genomic classifiers show promise in improving risk stratification after surgery, but limited data exist for patients treated with radiation therapy or in advanced stages of the disease. A systematic review and expert survey were conducted to evaluate the role of genomic classifiers in radiation therapy and identify future research areas for personalized treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Editorial Material
Oncology
Birgitte Vrou Offersen, Marianne C. Aznar, Carol Bacchus, Rob P. Coppes, Eric Deutsch, Dieter Georg, Karin Haustermans, Peter Hoskin, Mechthild Krause, Eric F. Lartigau, Anne W. M. Lee, Steffen Loeck, David I. Thwaites, Albert J. van der Kogel, Uulke van der Heide, Vincenzo Valentini, Jens Overgaard, Michael Baumann
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Lien Smets, Annelies Debucquoy, Eva Oldenburger, Chantal Van Audenhove, Lynn Debrun, Jeroen Dekervel, Gabriele Bislenghi, Andre D'Hoore, Albert Wolthuis, Karin Haustermans
Summary: This study developed a patient decision aid (PtDA) for rectal cancer patients with a clinical complete response after neo-adjuvant treatment, aiming to facilitate shared decision making. The results of the survey showed that most patients believed using a PtDA in clinical practice would be of added value in decision making.
Article
Oncology
Tiuri E. Kroese, Hanneke W. M. van Laarhoven, Sebastian F. Schoppman, Pieter R. A. J. Deseyne, Eric van Cutsem., Karin Haustermans., Philippe. Nafteux, Melissa Thomas, Radka Obermannova, Hanna R. Mortensen, Marianne Nordsmark, Per Pfeiffer, Anneli Elme, Antoine Adenis, Guillaume Piessen, Christiane J. Bruns, Florian Lordick, Ines Gockel, Markus Moehler, Cihan Gani, Theodore Liakakos, John Reynolds, Alessio G. Morganti, Riccardo Rosati, Carlo Castoro, Francesco Cellini, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Jolanda van Dieren, Marieke Vollebergh, Johanna W. van Sandick, Paul Jeene, Christel T. Muijs, Marije Slingerland, Francine E. M. Voncken, Henk Hartgrink, Geert-Jan Creemers, Maurice J. C. van der Sangen, Grard Nieuwenhuijzen, Maaike Berbee, Marcel Verheij, Bas Wijnhoven, Laurens V. Beerepoot, Nadia H. Mohammad, Stella Mook, Jelle P. Ruurda, Piotr Kolodziejczyk, Wojciech P. Polkowski, Lucjan Wyrwicz, Maria Alsina, Manuel Pera, Tania F. Kanonnikoff, Andres Cervantes, Magnus Nilsson, Stefan Monig, Anna D. Wagner, Matthias Guckenberger, Ewen A. Griffiths, Elizabeth Smyth, George B. Hanna, Sheraz Markar, M. Asif Chaudry, Maria A. Hawkins, Edward Cheong, Richard van Hillegersberg, Peter S. N. van Rossum
Summary: This study aimed to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophago-gastric cancer. Through a series of discussions and expert evaluations, a consensus was reached, which can be used for future research in clinical trials.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, Chris Verslype, Eric Van Cutsem, Tania Roskams, Sabine Tejpar, Isabelle Vanden Bempt, Jeroen Dekervel
Summary: Current systemic therapies for advanced cholangiocarcinoma (CCA) are limited in their effectiveness, but next-generation sequencing (NGS) technologies have provided a better understanding of the genetic basis of the disease. This study aimed to determine the proportion of actionable genetic alterations in CCA patients and evaluate the impact of targeted treatment on disease control.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, Marcus Unterrainer, Eric Van Cutsem, Chris Verslype, Frederik Cleeren, Christophe M. Deroose
Summary: Molecular imaging of somatostatin receptors is crucial in the clinical management of neuroendocrine tumors. PET imaging with 68Ga or 64Cu labeled somatostatin analogs is currently the gold standard, but practical and economic issues hinder widespread implementation of 68Ga imaging. Recent advancements in radiochemistry have enabled the use of 18F labeling, leading to promising clinical translations of 18F-labeled somatostatin analogs. This review presents updated clinical data and justifies the clinical application of these tracers.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Jos van Pelt, Bob Meeusen, Rita Derua, Liesbeth Guffens, Eric Van Cutsem, Veerle Janssens, Chris Verslype
Summary: Pancreatic ductal adenocarcinoma (PDAC) has a low survival and little therapeutic advancements are expected. Epithelial-to-Mesenchymal transition (EMT) and Protein Phosphatase Type 2A (PP2A) play a role in aggressive PDAC. This study investigates the relationship between PP2A expression signature and EMT, and explores treatment implications.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Medicine, General & Internal
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klumpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel
Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.
Article
Surgery
Thomas Winckelmans, Dennis A. A. Wicherts, Isabelle Parmentier, Celine De Meyere, Chris Verslype, Mathieu D'Hondt
Summary: This study compares the experience of robotic liver surgery (RLS) with conventional laparoscopic liver surgery (LLS). The results show that RLS has less blood loss, shorter length of stay, but higher surgical costs.
WORLD JOURNAL OF SURGERY
(2023)
Review
Oncology
M. Ducreux, G. K. Abou-Alfa, T. Bekaii-Saab, J. Berlin, A. Cervantes, T. de Baere, C. Eng, P. Galle, S. Gill, T. Gruenberger, K. Haustermans, A. Lamarca, P. Laurent-Puig, J. M. Llovet, F. Lordick, T. Macarulla, D. Mukherji, K. Muro, R. Obermannova, J. -M. O'Connor, E. M. O'Reilly, P. Osterlund, P. Philip, G. Prager, E. Ruiz-Garcia, B. Sangro, T. Seufferlein, J. Tabernero, C. Verslype, H. Wasan, E. Van Cutsem
Summary: This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is essential for optimal diagnosis, staging, and planning of curative and therapeutic options for HCC, considering factors such as liver cirrhosis.
Article
Oncology
Pieter Populaire, Gilles Defraene, Philippe Nafteux, Lieven Depypere, Johnny Moons, Sofie Isebaert, Karin Haustermans
Summary: This study aimed to investigate the relationship between dose to functional lung volumes (FLV) and treatment-related lung toxicity in locally advanced esophageal cancer (EC) patients. The results showed that an increase in FLV dose between 10 and 20 Gy and a decrease in anatomical lung volume (ALV) were associated with postoperative pulmonary complications.
Article
Ecology
Manon Coone, Karen Bisschop, Chris Verslype, Ellen Decaestecker
Summary: The interplay between the host and its associated microbiota plays a key role in the host's ability to tolerate hypoxic conditions. A gut transplant experiment with Daphnia magna revealed that individuals with a microbiome pre-exposed to hypoxia had a higher survival probability in hypoxic environments.
JOURNAL OF EVOLUTIONARY BIOLOGY
(2023)
Article
Oncology
Lisa De Cock, Cedric Draulans, Floris J. Pos, Sofie Isebaert, Robin De Roover, Uulke A. van der Heide, Robert J. Smeenk, Martina Kunze-Busch, Jochem van der Voort van Zyp, Hans de Boer, Linda G. W. Kerkmeijer, Karin Haustermans
Summary: The study aimed to investigate the safety of reducing the overall treatment time for focal boosted prostate stereotactic body radiotherapy. Results showed that the semi-weekly treatment schedule was associated with acceptable acute genitourinary and gastrointestinal toxicity. Compared to the once-weekly schedule, the semi-weekly treatment resulted in lower genitourinary toxicity and improved quality of life for the patients.
RADIOTHERAPY AND ONCOLOGY
(2023)